2016年6月24-25日，临床肿瘤学新进展学术研讨会——Best of ASCO Event in China2016在杭州召开。24日上午的淋巴瘤专场上，天津医科大学肿瘤医院淋巴瘤科主任、天津市抗癌协会淋巴瘤专业委员会主任委员张会来带来了三项淋巴瘤的重要研究报告。

三项研究摘要编号和题目：

Abstract 7504：Randomized phase III study onthe effect of early intensification of rituximab in combination with 2-weeklyCHOP chemotherapy followed by rituximab or no maintenance in patients withdiffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.

Abstract 7503：Two years rituximab maintenancevs. observation after first line treatment with bendamustine plus rituximab(B-R) in patients with mantle cell lymphoma: First results of a prospective,randomized,multicenter phase 2 study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

Abstract 7506：PILLAR-2: A randomized,double-blind, placebo-controlled, phase 3 study of adjuvant everolimus (EVE) inpatients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

直通车：黄慧强教授对淋巴瘤的三个重要研究进行评述

会议专题》》》2016临床肿瘤学新进展学术研讨会（BOA）